MR Imaging of Prostate Cancer: Diffusion Weighted Imaging and (3D) Hydrogen 1 (1H) MR Spectroscopy in Comparison with Histology

Purpose. To evaluate retrospectively the impact of diffusion weighted imaging (DWI) and (3D) hydrogen 1 (1H) MR-spectroscopy (MRS) on the detection of prostatic cancer in comparison to histological examinations. Materials and Methods: 50 patients with suspicion of prostate cancer underwent a MRI examination at a 1.5T scanner. The prostate was divided into sextants. Regions of interest were placed in each sextant to evaluate the apparent diffusion coefficient (ADC)-values. The results of the DWI as well as MRS were compared retrospectively with the findings of the histological examination. Sensitivity and specificity of ADC and metabolic ratio (MET)—both separately and in combination—for identification of tumor tissue was computed for variable discrimination thresholds to evaluate its receiver operator characteristic (ROC). An association between ADC, MET and Gleason score was tested by the non-parametric Spearman ρ-test. Results. The average ADC-value was 1.65 ± 0.32mm2/s × 10−3 in normal tissue and 0.96±0.24 mm2/s × 10−3 in tumor tissue (mean ± 1 SD). MET was 0.418 ± 0.431 in normal tissue and 2.010 ± 1.649 in tumor tissue. The area under the ROC curve was 0.966 (95%-confidence interval 0.941–0.991) and 0.943 (0.918–0.968) for DWI and MRS, respectively. There was a highly significant negative correlation between ADC-value and the Gleason score in the tumor-positive tissue probes (n = 62, ρ = −0.405, P = .001). MRS did not show a significant correlation with the Gleason score (ρ = 0.117, P = .366). By using both the DWI and MRS, the regression model provided sensitivity and specificity for detection of tumor of 91.9% and 98.3%, respectively. Conclusion. The results of our study showed that both DWI and MRS should be considered as an additional and complementary tool to the T2-weighted MRI for detecting prostate cancer.

[1]  E. Negri,et al.  Leveling of prostate cancer mortality in Western Europe , 2004, The Prostate.

[2]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.

[3]  B. Carey,et al.  Imaging for prostate cancer. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  K. Hosseinzadeh,et al.  Endorectal diffusion‐weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue , 2004, Journal of magnetic resonance imaging : JMRI.

[5]  T. Vogl,et al.  Staging des Prostatakarzinoms: Wertigkeit der kombinierten Information aus endorektaler MRT, bioptischem Gleason Score und präoperativem PSA-Wert , 2006 .

[6]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[7]  J R Thornbury,et al.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. , 1997, Radiology.

[8]  A. Wetter,et al.  [Staging of prostate cancer: value of the combined information of endorectal MRI, biopsy Gleason score, and preoperative PSA level]. , 2006, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[9]  M. Horsfield,et al.  Sensitivity-encoded diffusion tensor MR imaging of the cervical cord. , 2003, AJNR. American journal of neuroradiology.

[10]  S. Kyriazi,et al.  Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection , 2007, Acta radiologica.

[11]  J Kurhanewicz,et al.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. , 2000, The Journal of urology.

[12]  T L Chenevert,et al.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[14]  A. Hemal,et al.  Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut‐off value to predict malignancy of the peripheral zone , 2007, NMR in biomedicine.

[15]  Arend Heerschap,et al.  Fast acquisition‐weighted three‐dimensional proton MR spectroscopic imaging of the human prostate , 2004, Magnetic resonance in medicine.

[16]  B. Issa,et al.  In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo‐planar imaging , 2002, Journal of magnetic resonance imaging : JMRI.

[17]  H. Mertens,et al.  Stellenwert der Diffusionsbildgebung in der Diagnostik von Wirbelkörpermetastasen des Prostatakarzinoms im Vergleich zu anderen Primärtumoren , 2006 .

[18]  Takuya Ueda,et al.  Diffusion-Weighted Imaging of Prostate Cancer , 2005, Journal of computer assisted tomography.

[19]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[20]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[21]  T Hackländer,et al.  [Value of diffusion-weighted imaging for diagnosing vertebral metastases due to prostate cancer in comparison to other primary tumors]. , 2006, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[22]  Jason A Koutcher,et al.  Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. , 2008, Radiology.

[23]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  D. Le Bihan,et al.  Artifacts and pitfalls in diffusion MRI , 2006, Journal of magnetic resonance imaging : JMRI.

[25]  Takeo Ishigaki,et al.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. , 2007, European journal of radiology.

[26]  Jelle O. Barentsz,et al.  Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis , 2002, European Radiology.

[27]  P. Carroll,et al.  Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. , 1996, Radiology.

[28]  Takeo Ishigaki,et al.  Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate , 2005, Journal of magnetic resonance imaging : JMRI.

[29]  J. García-Segura,et al.  Comparison of digital rectal examination, transrectal ultrasonography, and multicoil magnetic resonance imaging for preoperative evaluation of prostate cancer. , 1997, European urology.

[30]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[31]  A. Villers,et al.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.

[32]  J Kurhanewicz,et al.  The prostate: MR imaging and spectroscopy. Present and future. , 2000 .

[33]  M. Meng,et al.  Imaging clinically localized prostate cancer. , 2003, The Urologic clinics of North America.

[34]  H. Hricak,et al.  Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging , 2000, Magnetic resonance in medicine.

[35]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[36]  L. Turnbull,et al.  Diffusion Imaging of the Prostate at 3.0 Tesla , 2006, Investigative radiology.

[37]  P. Carroll,et al.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. , 1994, Radiology.

[38]  P H Bland,et al.  Prostate cancer: correlation of MR images with tissue optical density at pathologic examination. , 1991, Radiology.

[39]  K. Taari,et al.  Endorectal magnetic resonance imaging of prostatic cancer: comparison between fat-suppressed T2-weighted fast spin echo and three-dimensional dual-echo, steady-state sequences , 2001, European Radiology.

[40]  K. Taari,et al.  Prostatic MR imaging: Accuracy in differentiating cancer from other prostatic disorders , 2001, Acta radiologica.

[41]  B. Hamm,et al.  Histopathologische Qualität von Prostatastanzzylindern: Vergleich einer MR-kompatiblen Biopsienadel mit einer im Ultraschall eingesetzten ferromagnetischen Biopsienadel , 2006 .

[42]  Kaoru Kurisu,et al.  Apparent diffusion coefficient of human brain tumors at MR imaging. , 2005, Radiology.

[43]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[44]  Stefan A Reinsberg,et al.  Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. , 2007, AJR. American journal of roentgenology.